Welcome to I See mantle cell lymphoma, a dedicated resource to help healthcare practitioners find the latest information about the signs, symptoms and diagnosis of MCL.
Mantle cell lymphoma (MCL) is a relatively rare, unique subcategory of B-cell non-Hodgkin lymphoma (NHL) with a generally aggressive clinical course.
Originally, MCL was classified with other types of lymphomas using different histology-based classification systems. MCL was only classified as a distinct subtype of B-cell NHL in the 1994 Revised European-American Lymphoma Classification (REAL). It was then confirmed in the World Health Organization (WHO) classification system.
MCL develops from changes to the outer edge, or mantle, of lymph nodes, causing the development of abnormal B-cells from that region. It can also affect the spleen, blood and bone marrow. MCL encompasses a wide range of biological and clinical variants. The majority of patients present with advanced stage disease and require systemic therapy.
A proposed model of molecular pathogenesis and progression of MCL.
Adapted from Dreyling et al. 2017.
The causes of MCL are mostly unknown; however, there are certain risk factors that are associated with the disease. These include:
MCL is a well-characterised B-cell lymphoma with markers readily detectable by immunohistochemistry
The majority of MCL cases also show expression of:
The more aggressive MCL subtypes, such as blastoid variants, display features such as:
The latest insights into diagnosing and treating AL amyloidosis.
Up-to-date information around identifying, diagnosing and treating WM.
Most recent guidance into diagnosing and treating AML.
A dedicated online resource for healthcare professionals to learn about the diagnosis and management of rare hematological malignancies: Waldenström's macroglobulinemia and mantle cell lymphoma.
This site has been developed by Janssen-Cilag International NV. Janssen-Cilag International NV is the responsible editor of this document.
ITEM CODE: CP-233134 | DATE OF PREPARATION: June 2021